Study of AZD4512 alone or with other drugs for leukemia
Part of Blood & lymphatic, Cancer, Immune system & allergy, Infections clinical trials.
This study tests a new medicine called AZD4512, given alone or with other cancer drugs, for people whose B-cell acute lymphoblastic leukemia (a type of blood cancer) has come back or not improved after treatment. The goal is to see if it can help control the disease.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are a teenager (at least 12 or 16 years old, depending on the study part).
- You have B-cell acute lymphoblastic leukemia (B-ALL) that is CD22-positive and has relapsed (returned) or is refractory (did not respond to treatment).
- You have received at least one or two prior treatments, depending on the study part, and the disease did not respond or came back.
- You are in reasonably good health (able to carry on daily activities) and your blast count (a type of white blood cell) is below a certain level.
- You have waited long enough after previous treatments, such as stem cell transplants or certain drugs, before joining this study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new investigational drug (AZD0486) given alone to see if it is safe and effective for people with B-cell acute lymphoblastic leukemia (ALL) that has come back or hasn't responded to treatment. It specifically targets a protein called CD19 found on leukemia cells.
This trial tests a new drug called AZD4512, alone or with other cancer treatments, for people whose B-cell non-Hodgkin lymphoma has come back or stopped responding to at least two prior therapies. It aims to find out if AZD4512 can help when standard options are limited.
This study tests an experimental drug called AZD3470 for people with certain types of blood cancer (lymphoma) that have come back or not responded to standard treatments. The drug will be given alone or with other cancer medicines to see if it is safe and effective.
This trial tests a new drug (AZD5492) that helps your immune system attack a protein (CD20) on cancer cells. It's for people with B-cell cancers that have come back after at least 2 prior treatments.
This trial is testing a new drug, AZD3632, either alone or with other cancer treatments, for people with advanced blood cancers that have specific genetic changes (like KMT2Ar, NPM1m, or others that cause HOX over-expression). The goal is to see if it can help when standard treatments have stopped working.
This trial tests a new drug, YK012, for people with a certain kind of B-cell acute lymphoblastic leukemia (B-ALL) that has returned or not gotten better after standard therapies. It aims to see if the drug is safe and works against these leukemia cells that have the CD19 marker.
Hear when a new B-cell Acute Lymphoblastic Leukemia (B-ALL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.